Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.

about

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

P2860

Q52724560-D0BB2A5D-8BAF-425F-96FD-62843F8FFBF4

P2860

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q51832606

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparison of two doses of int ...... fractory mantle cell lymphoma.

@en

Comparison of two doses of int ...... fractory mantle cell lymphoma.

@nl

type

Item

label

Comparison of two doses of int ...... fractory mantle cell lymphoma.

@en

Comparison of two doses of int ...... fractory mantle cell lymphoma.

@nl

prefLabel

Comparison of two doses of int ...... fractory mantle cell lymphoma.

@en

Comparison of two doses of int ...... fractory mantle cell lymphoma.

@nl

P1476

Comparison of two doses of int ...... efractory mantle cell lymphoma

@en

P2093

Agnieszka Giza

http://www.w3.org/2001/XMLSchema#string

Alessandra Romano

http://www.w3.org/2001/XMLSchema#string

Georg Hess

http://www.w3.org/2001/XMLSchema#string

Heidi Mocikova

http://www.w3.org/2001/XMLSchema#string

Jill Clancy

http://www.w3.org/2001/XMLSchema#string

Joseph Boni

http://www.w3.org/2001/XMLSchema#string

Mariajose Lechuga

http://www.w3.org/2001/XMLSchema#string

Michelle Casey

http://www.w3.org/2001/XMLSchema#string

Pratyush Giri

http://www.w3.org/2001/XMLSchema#string

Sundra Ramanathan

http://www.w3.org/2001/XMLSchema#string

P2860

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Targeting mTOR in mantle cell lymphoma: current and future directions.

P304

670-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1357175

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Wojciech Jurczak

P577

2017-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28768446

http://www.w3.org/2001/XMLSchema#string

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.

about

P2860

P2860

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698